Objectives | Endpoint | Assessment method | |
---|---|---|---|
Primary | To compare use of chemotherapy in the last 3 months of life in the control and intervention groups | Proportion of patients who receive chemotherapy at EoL | Numerical and descriptive data from HCP registrations/e-CRF, last 3 months before death |
Secondary | To examine the administration of chemotherapy last 3 months, medical interventions/treatments at EoL, after discontinuation of chemotherapy | Number of chemotherapy cycles, initiation, and discontinuation Proportion of patients who receive other medical interventions, i.e. concomitant medication and artificial nutrition | Numerical and descriptive data from HCP registrations/e-CRF, last 3 months of life, and after discontinuation of chemotherapy |
To compare PROs | Patient-reported symptom burden, QoL, anxiety/depression, satisfaction with information | EAPC basic dataset. EORTC-QLQ PAL15, PHQ-9, GAD-7, EORTC QLQ-INFO25 | |
To compare caregiver-reported outcomes | Caregiver-reported health, QoL, and satisfaction with care | SF-36, FAMCARE | |
Explorative | To examine length of survival | Length of survival from start of last line of chemotherapy | HCP registrations, Cause of Death Registry |
To examine direct costs | Costs of healthcare, oncology/palliative units | Length of stay, number of hospitalizations, anticancer and other medical interventions |